Detalhe da pesquisa
1.
Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).
Gynecol Oncol
; 178: 161-169, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37890345
2.
ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer.
Future Oncol
; 19(23): 1577-1591, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37334673
3.
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
N Engl J Med
; 381(25): 2403-2415, 2019 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31562800
4.
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.
J Clin Oncol
; 40(19): 2138-2147, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35290101
5.
Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat model.
Cancer Res
; 65(8): 3243-8, 2005 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15833856
6.
The impact of complete surgical staging on adjuvant treatment decisions in endometrial cancer.
Gynecol Oncol
; 93(2): 536-9, 2004 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15099975